NanoViricides, Inc. (NYSE American: NNVC) has announced that its Phase IIA clinical trial of NV-387 Oral Gummies for Ebola Bundibugyo virus disease in the Democratic Republic of Congo is advancing, with a Phase IIB stage anticipated after the initial phase concludes. Enrollment started on September 23, 2026, and approximately 20 patients are expected to participate in Phase IIA, which aims to evaluate dosing regimens based on disease severity. The primary endpoint is 28-day survival, and the phase will end once the last enrolled patient completes the observation period. The company’s progress is detailed in a recent press release available through this link.
The significance of this trial is heightened by the ongoing Ebola Bundibugyo outbreak in the DRC, which has produced more than 10,000 confirmed cases and approximately 4,900 deaths. Currently, no treatments or vaccines are approved specifically for Ebola Bundibugyo. NanoViricides states that NV-387 Oral Gummies is, to its knowledge, the only oral drug candidate in clinical evaluation for the disease. An oral antiviral could be particularly valuable in outbreak settings where healthcare infrastructure is limited, as it may simplify administration and improve patient access.
NanoViricides is a clinical-stage antiviral drug developer creating special-purpose nanomaterials for antiviral therapy. Its lead candidate, NV-387, is a broad-spectrum antiviral being developed for RSV, COVID-19, influenza, and other respiratory viral infections, as well as mpox/smallpox and measles. The company is also evaluating NV-387 Oral Gummies in a separate Phase II trial for mpox in the DRC. More information about NanoViricides is available on its website at www.nanoviricides.com.
For investors, the trial’s advancement represents a critical step in addressing an unmet medical need. The latest news and updates relating to NNVC are available in the company’s newsroom at https://ibn.fm/NNVC. The announcement was distributed via BioMedWire, a communications platform focused on biotechnology, biomedical sciences, and life sciences. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire and other services. Full terms of use and disclaimers are available at https://www.BioMedWire.com/Disclaimer.
